Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene

Kong,Ya; Lu,Zong-Liang; Wang,Jia-Jia; Zhou,Rui; Guo,Jing; Liu,Jie; Sun,Hai-Lan; Wang,He; Song,Wei; Yang,Jian; Xu,Hong-Xia

doi:10.3892/or.2016.4935

Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene

Authors:
- Ya Kong
- Zong-Liang Lu
- Jia-Jia Wang
- Rui Zhou
- Jing Guo
- Jie Liu
- Hai-Lan Sun
- He Wang
- Wei Song
- Jian Yang
- Hong-Xia Xu
View Affiliations

Affiliations: Department of Nutrition, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, P.R. China
Published online on: July 13, 2016 https://doi.org/10.3892/or.2016.4935
Pages: 1447-1456

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of the present study was to explore the in vitro and in vivo anticancer effects of Platycodin D (PD), derived from Platycodin grandiflorum, on highly metastatic MDA-MB-231 breast cancer cells. Using the MTT assay, we found that PD inhibited MDA-MB-231 cell growth in a concentration-dependent manner, with an IC50 value of 7.77±1.86 µM. Further studies showed that PD had anti-proliferative effects and induced cell cycle arrest in the G0/G1 phase. To explore the detailed mechanism(s) by which PD suppressed MDA-MB-231 cell growth, western blot analyses were used to detect the expression levels of proteins related to cell proliferation and survival. The data showed that PD decreased the expression of proteins related to the G0/G1 phases, downregulated the protein expression of MDM2, MDMX, and mutant p53, and increased the expression levels of p21 and p27 in vitro. We verified the effects of PD on the expression of MDM2, MDMX, mutant p53, p21 and p27 using a pcDNA3-Flag-MDM2 plasmid and MDM2 siRNA transfection, and found that PD inhibited MDA-MB-231 cell viability by targeting MDM2 and mutant p53. Compared with the corresponding parental cells, the cells with siRNA-MDM2 transfection had a greater decrease in cell viability and proliferation, while those with pcDNA3-MDM2 plasmid transfection did not show any increase in the effects of PD. We also established a MDA-MB-231 xenograft model in BALB/c nude mice, and found that PD significantly inhibited the growth of MDA-MB-231 xenograft tumors in these mice. The expression levels of various proteins in the tumor tissue exhibited changes similar to those observed in vitro. These findings indicate that PD exerted in vitro and in vivo anticancer effects against MDA-MB-231 breast cancer cells, that PD is a potential MDM2/MDMX inhibitor, and that the anticancer effects of PD were likely associated with its inhibition of these proteins. Our observations help to identify a mechanism by which PD functions as an anti-breast cancer agent.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ward EM, DeSantis CE, Lin CC, Kramer JL, Jemal A, Kohler B, Brawley OW and Gansler T: Cancer statistics: Breast cancer in situ. CA Cancer J Clin. 65:481–495. 2015. View Article : Google Scholar : PubMed/NCBI
3	Safdari Y, Khalili M, Ebrahimzadeh MA, Yazdani Y and Farajnia S: Natural inhibitors of PI3K/AKT signaling in breast cancer: Emphasis on newly-discovered molecular mechanisms of action. Pharmacol Res. 93:1–10. 2015. View Article : Google Scholar
4	Wu J, Yang G, Zhu W, Wen W, Zhang F, Yuan J and An L: Anti-atherosclerotic activity of platycodin D derived from roots of Platycodon grandiflorum in human endothelial cells. Biol Pharm Bull. 35:1216–1221. 2012. View Article : Google Scholar : PubMed/NCBI
5	Chung JW, Noh EJ, Zhao HL, Sim JS, Ha YW, Shin EM, Lee EB, Cheong CS and Kim YS: Anti-inflammatory activity of prosapogenin methyl ester of platycodin D via nuclear factor-kappaB pathway inhibition. Biol Pharm Bull. 31:2114–2120. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zhang T, Yang S, Du J, Jinfu Y and Shumin W: Platycodin D attenuates airway inflammation in a mouse model of allergic asthma by regulation NF-κB pathway. Inflammation. 38:1221–1228. 2015. View Article : Google Scholar
7	Zhao HL, Harding SV, Marinangeli CP, Kim YS and Jones PJ: Hypocholesterolemic and anti-obesity effects of saponins from Platycodon grandiflorum in hamsters fed atherogenic diets. J Food Sci. 73:H195–H200. 2008. View Article : Google Scholar : PubMed/NCBI
8	Lu Z, Wang L, Zhou R, Qiu Y, Yang L, Zhang C, Cai M, Mi M and Xu H: Evaluation of the spermicidal and contraceptive activity of Platycodin D, a Saponin from Platycodon grandiflorum. PLoS One. 8:e820682013. View Article : Google Scholar : PubMed/NCBI
9	Park JC, Lee YJ, Choi HY, Shin YK, Kim JD and Ku SK: In vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell. Evid Based Complement Alternat Med. 2014:4786532014. View Article : Google Scholar : PubMed/NCBI
10	Li T, Xu WS, Wu GS, Chen XP, Wang YT and Lu JJ: Platycodin D induces apoptosis, and inhibits adhesion, migration and invasion in HepG2 hepatocellular carcinoma cells. Asian Pac J Cancer Prev. 15:1745–1749. 2014. View Article : Google Scholar : PubMed/NCBI
11	Chun J, Joo EJ, Kang M and Kim YS: Platycodin D induces anoikis and caspase-mediated apoptosis via p38 MAPK in AGS human gastric cancer cells. J Cell Biochem. 114:456–470. 2013. View Article : Google Scholar
12	Zhou R, Lu Z, Liu K, Guo J, Liu J, Zhou Y, Yang J, Mi M and Xu H: Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo. Curr Cancer Drug Targets. 14:860–871. 2015. View Article : Google Scholar
13	Kim MO, Moon DO, Choi YH, Shin DY, Kang HS, Choi BT, Lee JD, Li W and Kim GY: Platycodin D induces apoptosis and decreases telomerase activity in human leukemia cells. Cancer Lett. 261:98–107. 2008. View Article : Google Scholar
14	Kim MO, Moon DO, Choi YH, Lee JD, Kim ND and Kim GY: Platycodin D induces mitotic arrest in vitro, leading to endoredu-plication, inhibition of proliferation and apoptosis in leukemia cells. Int J Cancer. 122:2674–2681. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chun J and Kim YS: Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways. Chem Biol Interact. 205:212–221. 2013. View Article : Google Scholar : PubMed/NCBI
16	Yu JS and Kim AK: Platycodin D induces apoptosis in MCF-7 human breast cancer cells. J Med Food. 13:298–305. 2010. View Article : Google Scholar : PubMed/NCBI
17	Ye Y, Han X, Guo B, Sun Z and Liu S: Combination treatment with platycodin D and osthole inhibits cell proliferation and invasion in mammary carcinoma cell lines. Environ Toxicol Pharmacol. 36:115–124. 2013. View Article : Google Scholar : PubMed/NCBI
18	Fakharzadeh SS, Trusko SP and George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1565–1569. 1991.PubMed/NCBI
19	Rayburn ER, Ezell SJ and Zhang R: Recent advances in validating MDM2 as a cancer target. Anticancer Agents Med Chem. 9:882–903. 2009. View Article : Google Scholar : PubMed/NCBI
20	Onel K and Cordon-Cardo C: MDM2 and prognosis. Mol Cancer Res. 2:1–8. 2004.PubMed/NCBI
21	Nag S, Qin J, Srivenugopal KS, Wang M and Zhang R: The MDM2-p53 pathway revisited. J Biomed Res. 27:254–271. 2013. View Article : Google Scholar : PubMed/NCBI
22	Brosh R and Rotter V: When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer. 9:701–713. 2009.PubMed/NCBI
23	Epstein CB, Attiyeh EF, Hobson DA, Silver AL, Broach JR and Levine AJ: p53 mutations isolated in yeast based on loss of transcription factor activity: Similarities and differences from p53 mutations detected in human tumors. Oncogene. 16:2115–2122. 1998. View Article : Google Scholar : PubMed/NCBI
24	Lee SK, Park KK, Kim HJ, Kim KR, Kang EJ, Kim YL, Yoon H, Kim YS and Chung WY: Platycodin D blocks breast cancer-induced bone destruction by inhibiting osteoclastogenesis and the growth of breast cancer cells. Cell Physiol Biochem. 36:1809–1820. 2015. View Article : Google Scholar : PubMed/NCBI
25	Tang ZH, Li T, Gao HW, Sun W, Chen XP, Wang YT and Lu JJ: Platycodin D from Platycodonis Radix enhances the anti-proliferative effects of doxorubicin on breast cancer MCF-7 and MDA-MB-231 cells. Chin Med. 9:162014. View Article : Google Scholar : PubMed/NCBI
26	Chun J, Ha IJ and Kim YS: Antiproliferative and apoptotic activities of triterpenoid saponins from the roots of Platycodon grandiflorum and their structure-activity relationships. Planta Med. 79:639–645. 2013. View Article : Google Scholar : PubMed/NCBI
27	Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 9:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
28	Hao Q and Cho WC: Battle against cancer: An everlasting saga of p53. Int J Mol Sci. 15:22109–22127. 2014. View Article : Google Scholar : PubMed/NCBI
29	Muller PA and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar
30	Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science. 253:49–53. 1991. View Article : Google Scholar : PubMed/NCBI
31	Freed-Pastor WA and Prives C: Mutant p53: One name, many proteins. Genes Dev. 26:1268–1286. 2012. View Article : Google Scholar : PubMed/NCBI
32	Rivlin N, Brosh R, Oren M and Rotter V: Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer. 2:466–474. 2011. View Article : Google Scholar : PubMed/NCBI
33	Kim BM, Kim DH, Park JH, Surh YJ and Na HK: Ginsenoside Rg3 inhibits constitutive activation of NF-κB signaling in human breast cancer (MDA-MB-231) cells: ERK and Akt as potential upstream targets. J Cancer Prev. 19:23–30. 2014. View Article : Google Scholar : PubMed/NCBI
34	Zhang Q, Zeng SX and Lu H: Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 85:281–319. 2014. View Article : Google Scholar : PubMed/NCBI
35	Pei D, Zhang Y and Zheng J: Regulation of p53: A collaboration between Mdm2 and Mdmx. Oncotarget. 3:228–235. 2012. View Article : Google Scholar : PubMed/NCBI
36	Qin JJ, Wang W, Voruganti S, Wang H, Zhang WD and Zhang R: Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Oncotarget. 6:2623–2640. 2015. View Article : Google Scholar : PubMed/NCBI
37	Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P: The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat. 19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI
38	Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH and Seth P: Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res. 1:889–897. 1995.PubMed/NCBI
39	Walerych D, Napoli M, Collavin L and Del Sal G: The rebel angel: Mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 33:2007–2017. 2012. View Article : Google Scholar : PubMed/NCBI